BRAF and neoplasm: Sorafenib is a multi-kinase inhibitor against VEGFR-1, VEGFR-2, VEGFR-3, BRAF, and c-Kit that downregulates both angiogenesis and tumor proliferation in multiple cancer cell lines [27,170,171].